Anticancer oral therapy: Emerging related issues

Cancer Treatment Reviews

Volumn 36, Issue 8, 2010, Pages 595-605

  Banna, Giuseppe Luigi ^a   Collovà, Elena ^b   Gebbia, Vittorio ^c   Lipari, Helga ^a   Giuffrida, Pietro ^a   Cavallaro, Sebastiano ^a   Condorelli, Rosaria ^a   Buscarino, Calogero ^a   Tralongo, Paolo ^d   Ferraù, Francesco ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b Hospital of Legnano   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d G Di Maria Hospital   (Italy)

^e San Vincenzo Hospital   (Italy)

Author keywords

Adherence; Cancer; Compliance; Cost; Drug drug interaction; Oraltherapy; Persistence; Pharmacogenomics; Pharmacokinetics; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GF 20918; IMATINIB; LAPATINIB; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; TEGAFUR; TOPOTECAN; UNCLASSIFIED DRUG; URACIL;

BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL METASTASIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HEALTH CARE ACCESS; HEALTH SERVICE; HOME CARE; HUMAN; KIDNEY FAILURE; MEDICAL ASSESSMENT; METASTASIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; PATIENT COMPLIANCE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 78349307556     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.04.005     Document Type: Review

References (92)

1. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.
2. Weingart S.N., Brown E., Bach P.B., et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008, 6(Suppl. 3):S1-S14.
3. Kuppens I.E., Breedveld P., Beijnen J.H., Schellens J.H. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005, 23:443-464.
4. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
5. Wojtacki J, Wiraszka R, Rolka-Stempniewicz G, et al. Breast cancer patients' preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006;159:abstr 381.
6. Paley M., Love N., Carlson R., et al. Preferences for oral, parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005, 23:619.
7. Fallowfield L., Atkins L., Catt S., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17:205-210.
8. Catania C., Didier F., Leon M.E., et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005, 92:265-272.
9. Pfeiffer P., Mortensen J.P., Bjerregaard B., et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006, 42:2738-2743.
10. Twelves C., Gollins S., Grieve R., Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006, 17:239-245.
11. Hennig I.M., Naik J.D., Brown S., et al. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. J Clin Oncol 2008, 26:3411-3417.
12. O'Neill V.J., Twelves C.J. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002, 87:933-937.
13. Decision Resources Survey. Oral chemotherapeutic agents: key success factors and reimbursement issues. A survey of US oncologists and HMO pharmacy directors. June 2005. Roche data on file, 2006.
14. Collovà E., Banna G., Fiorio E., et al. Opininions about the use of oral chemotherapy (CT) for cancer patients: results of a survey conducted among Italian oncologists. Ann Oncol 2009, 20:B51.
15. Ishikawa T., Utoh M., Sawada N., Nishida M., Fukase Y., Sekiguchi F., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998, 55:1091-1097.
16. Kelly H., Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005, 23:4553-4560.
17. Tabata T., Katoh M., Tokudome S., et al. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 2004, 32:762-767.
18. Lush R.M., McCune J.S., Tetteh L., et al. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 2005, 56:578-584.
19. Marty M., Fumoleau P., Adenis A., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001, 12:1643-1649.
20. Herben V.M., ten Bokkel Huinink W.W., Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996, 31:85-102.
21. Hande K., Messenger M., Wagner J., Krozely M., Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999, 5:2742-2747.
22. Toffoli G., Corona G., Sorio R., et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001, 52:511-519.
23. Kruijtzer C.M., Beijnen J.H., Rosing H., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002, 20:2943-2950.
24. Malingre M.M., Beijnen J.H., Rosing H., et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001, 84:42-47.
25. Maliepaard M., van Gastelen M.A., Tohgo A., et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001, 7:935-941.
26. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989, 16:215-237.
27. Gamelin E., Delva R., Jacob J., et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105.
28. de Jonge M.E., Huitema A.D., Schellens J.H., Rodenhuis S., Beijnen J.H. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol 2005, 59:325-334.
29. Rowinsky E.K., Lucas V.S., Hsieh A.L., et al. The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemother Pharmacol 1996, 39:9-16.
30. Ratain M.J., Cohen E.E. The value meal: how to save $1, 700 per month or more on lapatinib. J Clin Oncol 2007, 25:3397-3398.
31. Singh B.N., Malhotra B.K. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004, 43:1127-1156.
32. Li Z., Vachharajani N.N., Krishna R. On the assessment of effects of food on the pharmacokinetics of drugs in early development. Biopharm Drug Dispos 2002, 23:165-171.
33. Ratain M.J. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 2002, 20:1434-1435.
34. Damle B., Ravandi F., Kaul S., et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 2001, 7:517-523.
35. Sharma S. Patient selection for oral chemotherapy. Oncology (Williston Park) 2001, 15:33-35.
36. Findlay M., von Minckwitz G., Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008, 19:212-222.
37. Haller D.G., Cassidy J., Clarke S.J., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008, 26:2118-2123.
38. Beijnen J.H., Schellens J.H. Drug interactions in oncology. Lancet Oncol 2004, 5:489-496.
39. Riechelmann R.P., Del Giglio A. Drug interactions in oncology: how common are they?. Ann Oncol 2009, 20:1907-1912.
40. Del Giglio A., Miranda V., Fede A., et al. Adverse drug reactions, drug interactions as causes of hospital admission in oncology. J Clin Oncol 2009, 27:e20656.
41. Haddad A., Davis M., Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007, 15:251-257.
42. Bernard S.A., Bruera E. Drug interactions in palliative care. J Clin Oncol 2000, 18:1780-1799.
43. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005, 23:9359-9368.
44. Yung A., Vredenburgh J., Cloughesy T., et al. Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. J Clin Oncol 2004, 22:1555.
45. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
46. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332:901-906.
47. Thompson AM, Dewar J, Fahey T, et al. Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer. In: Breast Cancer Symposium, San Francisco, CA, 2007:abstr130.
48. Muss H.B., Berry D.A., Cirrincione C.T., et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
49. Joensuu H., Kellokumpu-Lehtinen P.L., Huovinen R., et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009, 10:1145-1151.
50. Maughan T., Adams R., Smith C., et al. 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer 2009, 7:4.
51. Cassidy J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clin Colorectal Cancer 2005, 5(Suppl. 1):S47-S50.
52. Partridge AH, Archer LE, Kornblith AB, et al. CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. J Clin Oncol 2008;26:abstr6542.
53. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94:652-661.
54. Lebovits A.H., Strain J.J., Schleifer S.J., Tanaka J.S., Bhardwaj S., Messe M.R. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65:17-22.
55. Lee C.R., Nicholson P.W., Souhami R.L., Deshmukh A.A. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992, 10:1007-1013.
56. Bonneterre J., Chevalier B., Focan C., Mauriac L., Piccart M. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 2001, 12:1683-1691.
57. Depierre A., Freyer G., Jassem J., et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001, 12:1677-1681.
58. Barron T.I., Connolly R., Bennett K., Feely J., Kennedy M.J. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007, 109:832-839.
59. Bickell N.A., Weidmann J., Fei K., Lin J.J., Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 2009, 27:5160-5167.
60. Waterhouse D.M., Calzone K.A., Mele C., Brenner D.E. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993, 11:1189-1197.
61. Faithfull S., Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004, 8(Suppl. 1):S54-62.
62. Chau I., Legge S., Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004, 8(Suppl. 1):S41-S53.
63. Molassiotis A., Brearley S., Saunders M., et al. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 2009, 27:6191-6198.
64. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
65. Colleoni M., Orlando L., Sanna G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006, 17:232-238.
66. Zaniboni A., Bolognesi A., Arnoldi E., Tabiadon D., Barni S., Intini C. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anticancer Drugs 1998, 9:295-299.
67. Barnadas A., Mendiola C., Casado A., et al. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer 1997, 33:312-315.
68. Nole F., Catania C., Munzone E., et al. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 2006, 6:518-524.
69. Tubiana-Mathieu N., Bougnoux P., Becquart D., et al. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 2009, 101:232-237.
70. Lorusso V, Spada M, Giampaglia M, et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 2006;17(Suppl. 7):vii15-7.
71. Finek J., Holubec L., Svoboda T., et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009, 29:667-670.
72. Nole F., Catania C., Sanna G., et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006, 17:322-329.
73. Kellokumpu-Lehtinen P.L., Sunela K., Lehtinen I., Joensuu H., Sjostrom-Mattson J. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006, 7:401-405.
74. Cameron DA, Afseth J, Murray E. Oral idarubicin and capecitabine: a dose finding study confirms this as a safe, effective 1st line therapy for older women with breast cancer. Breast Cancer Res Treat 2002;76:abstr 341.
75. Findlay M., Sharples K., Riley G., et al. Capecitabine and oral cyclophosphamide: a novel oral treatment combination for advanced cancer. Asia-Pacific J Clin Oncol 2007, 3:99-105.
76. Tong D.K., Cheng C.W., Ching Chan S., Ngor Wong L., Chow L.W. Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer-safety, efficacy and quality of life. Oncology 2005, 68:520-525.
77. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
78. Tan E.H., Rolski J., Grodzki T., et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009, 20:1249-1256.
79. Payne S.A. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992, 35:1505-1509.
80. Conroy T., Hebbar M., Bennouna J., et al. Quality-of-life findings from a randomised phase-III study of XELOX vs. FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2010, 102:59-67.
81. Kopec J.A., Yothers G., Ganz P.A., et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007, 25:424-430.
82. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001, 37:597-604.
83. Jansman F.G., Postma M.J., van Hartskamp D., Willemse P.H., Brouwers J.R. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004, 26:579-589.
84. Cassidy J., Douillard J.Y., Twelves C., et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs. intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006, 94:1122-1129.
85. Di Costanzo F., Ravasio R., Sobrero A., et al. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer: economic evaluation in an Italian NHS setting. Clin Drug Investig 2008, 28:645-655.
86. Douillard J.Y., Tilleul P., Ychou M., et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 2007, 72:248-254.
87. Shiroiwa T., Fukuda T., Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 2009, 101:12-18.
88. Silberman G, Gupta S, Berkowitz N, et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1999;18:abstr1629.
89. Baran RW, Dupere W, Susan M, et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. Proc Am Soc Clin Oncol 2002;21:abstr1942.
90. James R, Blanco C, Farina C. Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer. Eur J Cancer 2003;1(Suppl. 5):Abstr 271.
91. Gebbia V., Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005, 4:915-928.
92. Colomer R., Alba E., Gonzalez-Martin A., et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol 2010, 21:195-198.